Oppenheimer Trims Pharming Group (NASDAQ:PHAR) Target Price to $30.00

Pharming Group (NASDAQ:PHAR) had its price target decreased by Oppenheimer from $31.00 to $30.00 in a research note issued to investors on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a report on Thursday, October 24th.

Pharming Group Stock Performance

Shares of Pharming Group stock opened at $8.84 on Monday. The business’s fifty day simple moving average is $8.07 and its 200-day simple moving average is $8.51. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a market cap of $599.62 million, a PE ratio of -34.00 and a beta of 0.15. Pharming Group has a 52 week low of $6.65 and a 52 week high of $13.20.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The company had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. During the same period last year, the business earned $0.02 EPS. Equities analysts forecast that Pharming Group will post -0.15 earnings per share for the current year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,435 shares of the company’s stock after buying an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.